Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China
NCT Number: NCT07301333
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Changsha, Hunan, 410013, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HRS-6257
placebo
Time frame: from ICF signing date to Day 14 or Day 21 or Day 27
Time frame: 0 hour to 72 hour after administration
Time frame: 0 hour to 72 hour after administration
Time frame: 0 hour to 72 hour after administration
Time frame: 0 hour to 72 hour after administration
Time frame: 0 hour to 72 hour after administration
Time frame: 0 hour to 72 hour after administration
Time frame: Day 1 to Day 1 or Day 14
Time frame: from ICF signing date to Day 14
Shanghai Hengrui Pharmaceutical Co., Ltd.
Industry
A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05484414
Neurologic Manifestations, Pain
Miami, Florida, United States
View Trial DetailsNCT07703553
Injection Site Pain, Neurologic Manifestations
Sanliurfa, Outside of the US, Turkey (Türkiye)
View Trial DetailsNCT07533409
Communication Disorders, Learning Disabilities
Edirne, Turkey (Türkiye)
View Trial DetailsNCT07487610
Frailty, Nervous System Diseases
Edirne, Turkey (Türkiye)
View Trial Details